DentalCare Logo

What You Need to Know About the Coronavirus (COVID‑19) Pandemic

Course Number: 652

PDF

References / Additional Resources

  1. Johns Hopkins University & Medicine. Coronavirus Resource Center. COVID-19 Dashboard. Global Map. Accessed May 19, 2021.

  2. Huang N, Pérez P, Kato T, et al. SARS-CoV-2 infection of the oral cavity and saliva. Nat Med. 2021 Mar 25. doi: 10.1038/s41591-021-01296-8. Epub ahead of print.

  3. Martines RB, Ritter JM, Matkovic E, et al. Pathology and Pathogenesis of SARS-CoV-2 Associated with Fatal Coronavirus Disease, United States. Emerg Infect Dis. 2020 Sep;26(9):2005-2015. doi: 10.3201/eid2609.202095. Epub 2020 May 21.

  4. Pascolo L, Zupin L, Melato M, et al. TMPRSS2 and ACE2 Coexpression in SARS-CoV-2 Salivary Glands Infection. J Dent Res. 2020 Sep;99(10):1120-1121. doi: 10.1177/0022034520933589. Epub 2020 Jun 1.

  5. Song J, Li Y, Huang X, et al. Systematic analysis of ACE2 and TMPRSS2 expression in salivary glands reveals underlying transmission mechanism caused by SARS-CoV-2. J Med Virol. 2020 Nov;92(11):2556-2566. doi: 10.1002/jmv.26045. Epub 2020 Jun 9.

  6. Liu L, Wei Q, Alvarez X, et al. Epithelial cells lining salivary gland ducts are early target cells of severe acute respiratory syndrome coronavirus infection in the upper respiratory tracts of rhesus macaques. J Virol. 2011 Apr;85(8):4025-30. doi: 10.1128/JVI.02292-10. Epub 2011 Feb 2.

  7. Regev A, Teichmann SA, Lander ES, et al. The Human Cell Atlas. Elife. 2017 Dec 5;6:e27041. doi: 10.7554/eLife.27041.

  8. Biology Dictionary. Tropism. Accessed May 19, 2021.

  9. Herrera D, Serrano J, Roldán S, Sanz M. Is the oral cavity relevant in SARS-CoV-2 pandemic? Clin Oral Investig. 2020 Aug;24(8):2925-2930. doi: 10.1007/s00784-020-03413-2. Epub 2020 Jun 23.

  10. Atukorallaya DS, Ratnayake RK. Oral Mucosa, Saliva, and COVID-19 Infection in Oral Health Care. Front Med (Lausanne). 2021 Apr 22;8:656926. doi: 10.3389/fmed.2021.656926.

  11. Zhu J, Guo J, Xu Y, Chen X. Viral dynamics of SARS-CoV-2 in saliva from infected patients. J Infect. 2020 Sep;81(3):e48-e50. doi: 10.1016/j.jinf.2020.06.059. Epub 2020 Jun 25.

  12. WHO. Emergencies preparedness, response. What is a pandemic? 2020 Feb 24. Accessed May 19, 2021.

  13. Pandemic Influenza Preparedness and Response: A WHO Guidance Document. Geneva: World Health Organization; 2009. 4, The WHO Pandemic Phases.

  14. Viboud C, Simonsen L, Chowell G. A generalized-growth model to characterize the early ascending phase of infectious disease outbreaks. Epidemics. 2016 Jun;15:27-37. doi: 10.1016/j.epidem.2016.01.002. Epub 2016 Feb 1.

  15. CDC. Influenza (Flu). Pandemic Influenza. Past Pandemics. 1918 Pandemic (H1N1 virus). 2019 Mar 20. Accessed May 19, 2021.

  16. CDC. Influenza (Flu). Pandemic Influenza. Past Pandemics. 1957-1958 Pandemic (H2N2 virus). 2019 Jan 2. Accessed May 19, 2021.

  17. CDC. About CDC 24-7. CDC SARS Response Timeline. 2013 Apr 26. Accessed May 19, 2021.

  18. Chan PK, Chan MC. Tracing the SARS-coronavirus. J Thorac Dis. 2013 Aug;5 Suppl 2(Suppl 2):S118-21. doi: 10.3978/j.issn.2072-1439.2013.06.19.

  19. de Wilde AH, Snijder EJ, Kikkert M, van Hemert MJ. Host Factors in Coronavirus Replication. Curr Top Microbiol Immunol. 2018;419:1-42. doi: 10.1007/82_2017_25.

  20. CDC. COVID-19. Common Human Coronaviruses. 2020 Feb 13. Accessed May 19, 2021.

  21. WHO. Transmission of SARS-CoV-2: implications for infection prevention precautions: Scientific Brief. 2020 Jul 9. Accessed May 19, 2021.

  22. Buzhdygan TP, DeOre BJ, Baldwin-Leclair A, et al. The SARS-CoV-2 spike protein alters barrier function in 2D static and 3D microfluidic in-vitro models of the human blood-brain barrier. Neurobiol Dis. 2020 Dec;146:105131. doi: 10.1016/j.nbd.2020.105131. Epub 2020 Oct 11.

  23. Altmann DM, Boyton RJ. SARS-CoV-2 T cell immunity: Specificity, function, durability, and role in protection. Sci Immunol. 2020 Jul 17;5(49):eabd6160. doi: 10.1126/sciimmunol.abd6160.

  24. Figueiredo-Campos P, Blankenhaus B, Mota C, et al. Seroprevalence of anti-SARS-CoV-2 antibodies in COVID-19 patients and healthy volunteers up to 6 months post disease onset. Eur J Immunol. 2020 Dec;50(12):2025-2040. doi: 10.1002/eji.202048970. Epub 2020 Nov 10.

  25. Song P, Li W, Xie J, Hou Y, You C. Cytokine storm induced by SARS-CoV-2. Clin Chim Acta. 2020 Oct;509:280-287. doi: 10.1016/j.cca.2020.06.017. Epub 2020 Jun 10.

  26. Johnson BS, Laloraya M. A cytokine super cyclone in COVID-19 patients with risk factors: the therapeutic potential of BCG immunization. Cytokine Growth Factor Rev. 2020 Aug;54:32-42. doi: 10.1016/j.cytogfr.2020.06.014. Epub 2020 Jul 1.

  27. Fajgenbaum DC, June CH. Cytokine Storm. N Engl J Med. 2020 Dec 3;383(23):2255-2273. doi: 10.1056/NEJMra2026131.

  28. Costela-Ruiz VJ, Illescas-Montes R, Puerta-Puerta JM, Ruiz C, Melguizo-Rodríguez L. SARS-CoV-2 infection: The role of cytokines in COVID-19 disease. Cytokine Growth Factor Rev. 2020 Aug;54:62-75. doi: 10.1016/j.cytogfr.2020.06.001. Epub 2020 Jun 2.

  29. Hasan A, Palmer RM. A clinical guide to periodontology: pathology of periodontal disease. Br Dent J. 2014 Apr;216(8):457-61. doi: 10.1038/sj.bdj.2014.299.

  30. Ripperger TJ, Uhrlaub JL, Watanabe M, et al. Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance of Low-Prevalence Communities and Reveal Durable Humoral Immunity. Immunity. 2020 Nov 17;53(5):925-933.e4. doi: 10.1016/j.immuni.2020.10.004. Epub 2020 Oct 14.

  31. Long QX, Tang XJ, Shi QL, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020 Aug;26(8):1200-1204. doi: 10.1038/s41591-020-0965-6. Epub 2020 Jun 18.

  32. Plüddemann A, Aronson JK. What is the role of T cells in COVID-19 infection? Why immunity is about more than antibodies. Oxford COVID-19 Evidence Service Team, Centre for Evidence-Based Medicine, Nuffield Department of Primary Care Health Sciences, University of Oxford. 2020 Oct 19. Accessed May 19, 2021.

  33. Delves PJ. Overview of the Immune System. Mereck Manual Consumer Version. 2020 Apr. Accessed May 19, 2021.

  34. Conlon A, Ashur C, Washer L, Eagle KA, Hofmann Bowman MA. Impact of the influenza vaccine on COVID-19 infection rates and severity. Am J Infect Control. 2021 Feb 22:S0196-6553(21)00089-4. doi: 10.1016/j.ajic.2021.02.012. Epub ahead of print.

  35. Chumakov K, Benn CS, Aaby P, Kottilil S, Gallo R. Can existing live vaccines prevent COVID-19? Science. 2020 Jun 12;368(6496):1187-1188. doi: 10.1126/science.abc4262.

  36. Blok BA, Arts RJ, van Crevel R, Benn CS, Netea MG. Trained innate immunity as underlying mechanism for the long-term, nonspecific effects of vaccines. J Leukoc Biol. 2015 Sep;98(3):347-56. doi: 10.1189/jlb.5RI0315-096R. Epub 2015 Jul 6.

  37. Cirovic B, de Bree LCJ, Groh L, et al. BCG Vaccination in Humans Elicits Trained Immunity via the Hematopoietic Progenitor Compartment. Cell Host Microbe. 2020 Aug 12;28(2):322-334.e5. doi: 10.1016/j.chom.2020.05.014. Epub 2020 Jun 15.

  38. CDC. COVID-19. Assessing Risk Factors for Severe COVID-19 Illness. 2020 Nov 30. Accessed May 19, 2021.

  39. Mayo Clinic. COVID-19: Who's at higher risk of serious symptoms? 2021 Apr 30. Accessed May 19, 2021.

  40. COVID-19 Event Risk Assessment Planning Tool. Accessed May 19, 2021.

  41. Barnkob MB, Pottegård A, Støvring H, et al. Reduced prevalence of SARS-CoV-2 infection in ABO blood group O. Blood Adv. 2020 Oct 27;4(20):4990-4993. doi: 10.1182/bloodadvances.2020002657. Accessed May 19, 2021.

  42. Barnkob MB, Pottegård A, Støvring H, Haunstrup TM, Homburg K, Larsen R, Hansen MB, Titlestad K, Aagaard B, Møller BK, Barington T. Reduced prevalence of SARS-CoV-2 infection in ABO blood group O. Blood Adv. 2020 Oct 27;4(20):4990-4993. doi: 10.1182/bloodadvances.2020002657.

  43. Rao S, Warrior S, Gezer S, et al. Impact of Blood Group Type on Severity of Disease in COVID-19 Patients. Blood. 2020 Nov 5;136(Supplement 1):29. doi: 10.1182/blood-2020-139021. Accessed May 19, 2021.

  44. Zeberg H, Pääbo S. The major genetic risk factor for severe COVID-19 is inherited from Neanderthals. Nature. 2020 Nov;587(7835):610-612. doi: 10.1038/s41586-020-2818-3. Epub 2020 Sep 30.

  45. Zeberg H, Pääbo S. A genomic region associated with protection against severe COVID-19 is inherited from Neandertals. Proc Natl Acad Sci U S A. 2021 Mar 2;118(9):e2026309118. doi: 10.1073/pnas.2026309118.

  46. Karim M, Dunham I, Ghoussaini M. Mining a GWAS of Severe Covid-19. N Engl J Med. 2020 Dec 24;383(26):2588-2589. doi: 10.1056/NEJMc2025747. Epub 2020 Nov 24.

  47. CDC. COVID-19. People with Certain Medical Conditions.2021 May 13. Accessed May 19, 2021.

  48. FDA. Press Announcemnts. FDA Approves First Treatment for COVID-19. 2020 Oct 22. Accessed May 19, 2021.

  49. WHO. WHO recommends against the use of remdesivir in COVID-19 patients. 2020 Nov 20

  50. Crist C. FDA Authorizes Regeneron COVID Antibody Treatment. WebMD. 2020 Nov 23. Accessed May 19, 2021.

  51. FDA. Press Announcemnts. Coronavirus (COVID-19) Update: FDA Authorizes Monoclonal Antibodies for Treatment of COVID-19. 2020 Nov 21. Accessed May 19, 2021.

  52. RECOVERY Collaborative Group, Horby P, Lim WS, et al. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021 Feb 25;384(8):693-704. doi: 10.1056/NEJMoa2021436. Epub 2020 Jul 17.

  53. NIH. COVID-19 Treatment Guidelines. What's New in the Guidelines. 2021 Apr 21. Accessed May 19, 2021.

  54. FDA. Press Announcemnts. Coronavirus (COVID-19) Update: FDA Authorizes Drug Combination for Treatment of COVID-19. 2020 Nov 19. Accessed May 19, 2021.

  55. NIH. New Releases. Investigational COVID-19 therapeutics to be evaluated in large clinical trials. 2020 Dec 17. Accessed May 19, 2021.

  56. FDA. Coronavirus Disease 2019 (COVID-19) Emergency Use Authorizations for Medical Devices. In Vitro Diagnostics EUAs. 2021 Apr 20. Accessed May 19, 2021.

  57. Johansson MA, Quandelacy TM, Kada S, et al. SARS-CoV-2 Transmission From People Without COVID-19 Symptoms. JAMA Netw Open. 2021 Jan 4;4(1):e2035057. doi: 10.1001/jamanetworkopen.2020.35057. Erratum in: JAMA Netw Open. 2021 Feb 1;4(2):e211383.

  58. Fozouni P, Son S, Díaz de León Derby M, et al. Amplification-free detection of SARS-CoV-2 with CRISPR-Cas13a and mobile phone microscopy. Cell. 2021 Jan 21;184(2):323-333.e9. doi: 10.1016/j.cell.2020.12.001. Epub 2020 Dec 4.

  59. NIH. New Releases. NIH-funded COVID-19 home test is first to receive over-the-counter authorization from FDA. 2020 Dec 15. Accessed May 19, 2021.

  60. National Academies of Sciences, Engineering, and Medicine. Framework for Equitable Allocation of COVID-19 Vaccine. Kahn B, Brown L, Foege W, Gayle H, editors. Washington (DC): National Academies Press (US); 2020 Oct 2.

  61. Zimmer C, Corum J, Wee S. Coronavirus Vaccine Tracker. The New York Times. 2021 May 10. Accessed May 19, 2021.

  62. FDA. Vaccines and Related Biological Products Advisory Committee Meeting. FDA Briefing Document. Pfizer-BioNTech COVID-19 Vaccine. 2020 Dec 10. Accessed May 19, 2021.

  63. Pfizer. Manufacturing and Distributing the COVID-19 Vaccine. Accessed May 19, 2021.

  64. [CDC. COVID-19. Interim Public Health Recommendations for Fully Vaccinated People. 2021 May 13.](CDC. COVID-19. Interim Public Health Recommendations for Fully Vaccinated People. 2021 May 13.) Accessed May 19, 2021.

  65. DiPiazza AT, Graham BS, Ruckwardt TJ. T cell immunity to SARS-CoV-2 following natural infection and vaccination. Biochem Biophys Res Commun. 2021 Jan 29;538:211-217. doi: 10.1016/j.bbrc.2020.10.060. Epub 2020 Oct 23.

  66. Twitter. Monica Gandhi, MD, MPH, professor of Medicine and Associate Division Chief (Clinical Operations/ Education) of the Division of HIV, Infectious Diseases, and Global Medicine at University of California, San Francisco (UCSF)/ San Francisco General Hospital. Accessed May 19, 2021.

  67. CDC. COVID-19. Vaccines. Understanding How COVID-19 Vaccines Work. 2021 Mar 9. Accessed May 19, 2021.

  68. [CDC. COVID-19. Vaccines. Different COVID-19 Vaccines. 2021 May 13.](CDC. COVID-19. Vaccines. Different COVID-19 Vaccines. 2021 May 13.) Accessed May 19, 2021.

  69. National Academies of Sciences, Engineering, and Medicine. Framework for Equitable Allocation of COVID-19 Vaccine. Kahn B, Brown L, Foege W, Gayle H, editors. Washington (DC): National Academies Press (US); 2020 Oct 2.

  70. [Treisman R. The Coronavirus Crisis. Biden Says All Adults Will Be Vaccine Eligible By April 19. NPR. 2021 Apr 6.](Treisman R. The Coronavirus Crisis. Biden Says All Adults Will Be Vaccine Eligible By April 19. NPR. 2021 Apr 6.) Accessed May 19, 2021.

  71. State of California. Department of Consumer Affairs. Order Waiving Restrictions on Dentists Relating to Ordering and Administering COVID-19 Vaccines. 2021 Jan 4. Accessed May 19, 2021.

  72. Garvin J. Dentists, dental students among providers now authorized to administer COVID-19 vaccine nationwide. ADA News. 2021 Mar 21. Accessed May 19, 2021.

  73. ADHA. COVID-19 Resource Center for Dental Hygienists. Accessed May 19, 2021.

  74. ADA. CDC-NCRID COVID-19 Coalition Letter. 2020 Dec 16. Accessed May 19, 2021.

  75. NIH. Newroom. Bulletin—Update on SARS-CoV-2 Variants. 2021 Jan 27. Accessed May 19, 2021.

  76. Arashkia A, Jalilvand S, Mohajel N, Afchangi A, et al. Severe acute respiratory syndrome-coronavirus-2 spike (S) protein based vaccine candidates: State of the art and future prospects. Rev Med Virol. 2020 Oct 15:e2183. doi: 10.1002/rmv.2183. Epub ahead of print.

  77. CDC. COVID-19. About Variants of the Virus that Causes COVID-19. 2021 Apr 2. Accessed May 19, 2021.

  78. Hacisuleyman E, Hale C, Saito Y, et al. Vaccine Breakthrough Infections with SARS-CoV-2 Variants. N Engl J Med. 2021 Apr 21. doi: 10.1056/NEJMoa2105000. Epub ahead of print.

  79. Liu Y, Liu J, Xia H, et al. Neutralizing Activity of BNT162b2-Elicited Serum. N Engl J Med. 2021 Apr 15;384(15):1466-1468. doi: 10.1056/NEJMc2102017. Epub 2021 Mar 8.

  80. WHO. COVID-19 and mandatory vaccination: Ethical considerations and caveats. 2021 Apr 13. Accessed May 19, 2021.

  81. [WHO. "Immunity passports" in the context of COVID-19. Scientific Brief. 2020 Apr 24.](WHO. "Immunity passports" in the context of COVID-19. Scientific Brief. 2020 Apr 24.) Accessed May 19, 2021.

  82. WHO. Coronavirus disease (COVID-19): Herd immunity, lockdowns and COVID-19. 2020 Dec 31. Accessed May 19, 2021.

  83. Mayo Clinic. Herd immunity and COVID-19 (coronavirus): What you need to know. 2021 May 5. Accessed May 19, 2021.

  84. Booker B. Fauci Predicts U.S. Could See Signs Of Herd Immunity By Late March Or Early April. NPR. 2020 Dec 15. Accessed May 19, 2021.

  85. Delamater PL, Street EJ, Leslie TF, Yang YT, Jacobsen KH. Complexity of the Basic Reproduction Number (R0). Emerg Infect Dis. 2019 Jan;25(1):1-4. doi: 10.3201/eid2501.171901.

  86. Bailey R. What's the Herd Immunity Threshold for the COVID-19 Coronavirus? Reason. 2020 May 15. Accessed May 19, 2021.

  87. Sahni V, Gupta S. COVID-19 & Periodontitis: The cytokine connection. Med Hypotheses. 2020 Nov;144:109908. doi: 10.1016/j.mehy.2020.109908. Epub 2020 May 30.

  88. Marouf N, Cai W, Said KN, et al. Association between periodontitis and severity of COVID-19 infection: A case-control study. J Clin Periodontol. 2021 Apr;48(4):483-491. doi: 10.1111/jcpe.13435. Epub 2021 Feb 15.

  89. Lloyd-Jones G, Molayem S, Pontes CC, Chapple I. The COVID-19 Pathway: A Proposed Oral-Vascular-Pulmonary Route Of SARS-CoV-2 Infection And The Importance Of Oral Healthcare Measures. Oral Med and Dent Res. 2021;2(1):S1. 2021 Apr 20. Accessed May 19, 2021.

  90. Sergis A, Wade WG, Gallagher JE, et al. Mechanisms of Atomization from Rotary Dental Instruments and Its Mitigation. J Dent Res. 2021 Mar;100(3):261-267. doi: 10.1177/0022034520979644. Epub 2020 Dec 16.

  91. CDC. COVID-19. Symptoms of COVID-19. 2021 Feb 22. Accessed May 19, 2021.

Additional Resources


0/17Next